Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation

This is an interventional treatment trial for Prolymphocytic Leukemia Read More

Inclusion Criteria:

• World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status =< 2
• Life expectancy >= 2 months

• Appropriate histologic diagnosis (a) or (b):

  • (a) Histologically documented diagnosis of intermediate or high risk CLL/SLL, B-PLL, and RT arising from CLL/SLL according to the 2008 guidelines, meeting criteria for active disease requiring treatment:

    • Evidence of marrow failure as manifested by the development or worsening of anemia or thrombocytopenia (not attributable to autoimmune hemolytic anemia or thrombocytopenia)
    • Massive (>= 6 cm below the costal margin), progressive or symptomatic splenomegaly
    • Massive nodes (>= 10 cm) or progressive or symptomatic lymphadenopathy
    • Autoimmune anemia and/or thrombocytopenia that is poorly responsive to standard therapy

    • Constitutional symptoms including any of the following:

      • Unintentional weight loss of 10% or more within 6 mos.
      • Significant fatigue limiting activity
      • Fevers >= 100.5 degrees F for 2 weeks or more without evidence of infection
      • Night sweats > 1 month without evidence of infection
    • Need for cytoreduction prior to stem cell transplantation
  • (b) Pathologically documented MCL [defined as either t(11;14) or overexpression of cyclin D1] for the MCL pilot study
• Relapsed after or refractory to at least one prior therapy
• Willingness to undergo all study-related evaluations and procedures
• Ability to understand and willingness to execute a written informed consent document

Exclusion Criteria:

• Prior therapy as follows:

  • Major surgery within 2 weeks
  • Corticosteroids greater than 20 mg/day prednisone (or equivalent) within 2 weeks unless used by inhalation or topical route, or unless necessary for premedication before iodinated contrast dye, or for autoimmune hemolytic anemia
  • Cytotoxic chemotherapy or biologic therapy within 4 weeks, excepting BCR kinase inhibitors for which no wash out is required, or
  • Nitrosoureas within the 6 weeks of the planned first dose of the study drug
• Failure to recover toxicity from prior chemo- or radiotherapy to grade 1
• Known active leukemia or lymphoma of the central nervous system (CNS) requiring therapy
• Inadequate bone marrow function/hematopoietic reserve, except in the case of documented bone-marrow involvement: absolute neutrophil count (ANC) < 1 x 10^9/L
• Inadequate bone marrow function/hematopoietic reserve, except in the case of documented bone-marrow involvement: platelets < 30 x 10^9/L
• Serum total bilirubin > 2 x ULN (upper limit of normal)
• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 x ULN, or > 5 x ULN if CLL/lymphoma is present in the liver
• Estimated glomerular filtration rate (GFR) < 30 mL/min
• Patients who are receiving treatment with medications that are known to be strong inducers or inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4/5 (CYP3A4/5) and CYP3A4/5 substrates with QT prolongation risk that cannot be discontinued prior to study entry

• Clinically significant cardiac diseases, including any of the following:

  • History or presence of ventricular tachyarrhythmia
  • Presence of unstable/uncontrolled atrial fibrillation (with ventricular rate > 100 beats per minute [bpm]); patients with stable atrial fibrillation are eligible provided that they do not meet any of the other exclusion criteria
  • Angina pectoris or acute myocardial infarction within 3 months of starting study drug
  • New York Heart Association (NYHA) functional class III or IV heart failure
  • Labile or uncontrolled hypertension
• History of another malignancy that limits survival to less than 2 years in the estimate of the investigator; basal and squamous cell cancers of the skin, or squamous cell carcinoma of the cervix in situ, which were completely resected or otherwise cured, or localized prostate cancer (Gleason < 5) are eligible
• Gastrointestinal dysfunction, including motility or malabsorption syndromes or inflammatory bowel disease which could limit absorption of AEB071
• Known human immunodeficiency virus (HIV) positivity, or active hepatitis B or C infection with detectible viral nucleic acid in the blood; testing for these viruses is not a required part of screening
• Severe systemic infections requiring intravenous antibiotics within the two weeks prior to initiation of AEB071
• Lactating or pregnant

• Women of child-bearing potential or male partners of women of child-bearing potential who will not agree to use highly effective method of contraception throughout the entire study period and for a minimum of 5 terminal half-lives of AEB071 (approximately 36 hours) after the last dose of study drug; highly effective contraception methods include:

  • Total abstinence or
  • Male or female sterilization or

  • Combination of any two of the following (a+b or a+c or b+c):

    • a. Use of oral, injected or implanted hormonal methods of contraception
    • b. Placement of an intrauterine device (IUD) or intrauterine system (IUS)
    • c. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago; in the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of childbearing potential
• Any other life-threatening illness or medical condition that, in the opinion of the investigator, could compromise the safety of the patient or interfere with analysis of study endpoints